论文部分内容阅读
目的探讨诺和灵30R与诺和锐30治疗2型糖尿病的临床疗效。方法 86例2型糖尿病患者,随机分为A组和B组,每组43例,A组患者利用诺和灵30R进行治疗,B组患者利用诺和锐30进行治疗。比较两组患者临床治疗效果。结果两组患者治疗后,其血糖值都较治疗前有明显降低(P<0.05);餐后2 h FPG下降值比较,B组下降幅度更加明显,差异具有统计学意义(P<0.05)。A组不良反应发生率为25.58%,B组患者不良反应发生率明显低于A组,差异具有统计学意义(P<0.05)。结论采用诺和锐30进行2型糖尿病的治疗,可以有效快速降低患者血糖,缓解患者血糖升高,安全、有效,值得临床推广应用。
Objective To investigate the clinical efficacy of Novolin 30R and Novartis 30 in the treatment of type 2 diabetes mellitus. Methods Totally 86 patients with type 2 diabetes mellitus were randomly divided into group A and group B, with 43 patients in each group. Patients in group A were treated with Novolin 30R, and patients in group B were treated with Novolin 30. The clinical effects of two groups were compared. Results After treatment, the blood glucose levels of both groups were significantly lower than those before treatment (P <0.05). The decrease of FPG at 2 h after meal was more obvious in group B (P <0.05). The incidence of adverse reactions in group A was 25.58%, and the incidence of adverse reactions in group B was significantly lower than that in group A, the difference was statistically significant (P <0.05). Conclusions The use of Novo-Rui 30 in the treatment of type 2 diabetes can effectively and quickly reduce the blood sugar, relieve the patient’s elevated blood sugar, safe and effective, worthy of clinical application.